BRCA1 Carriers and Oral Contraceptives - Risk-benefit Calculation on Breast and Ovarian Cancer

被引：0
|
作者：
Schrijver, L. H. [1 ]
Rookus, M. A. [1 ]
Mooij, T. M. [1 ]
Pijpe, A. [1 ]
van Leeuwen, F. E. [1 ]
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [41] Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS)
    MA Rookus
    RM Brohet
    N Andrieu
    AC Antoniou
    J Chang-Claude
    DF Easton
    S Peock
    C Noguès
    FE van Leeuwen
    DE Goldgar
    Breast Cancer Research, 7
  • [42] Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS)
    Rookus, MA
    Brohet, RM
    Andrieu, N
    Antoniou, AC
    Chang-Claude, J
    Easton, DF
    Peock, S
    Noguès, C
    van Leeuwen, FE
    Goldgar, DE
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S20 - S21
  • [43] Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
    Leendert H Zaaijer
    Helena C van Doorn
    Marian J E Mourits
    Marc van Beurden
    Joanne A de Hullu
    Muriel A Adank
    Luc R C W van Lonkhuijzen
    Hans F A Vasen
    Brigitte F M Slangen
    Katja N Gaarenstroom
    Ronald P Zweemer
    Peggy M L H Vencken
    Caroline Seynaeve
    Mieke Kriege
    British Journal of Cancer, 2016, 115 : 1174 - 1178
  • [44] Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
    Zaaijer, Leendert H.
    van Doorn, Helena C.
    Mourits, Marian J. E.
    van Beurden, Marc
    de Hullu, Joanne A.
    Adank, Muriel A.
    van Lonkhuijzen, Luc R. C. W.
    Vasen, Hans F. A.
    Slangen, Brigitte F. M.
    Gaarenstroom, Katja N.
    Zweemer, Ronald P.
    Vencken, Peggy M. L. H.
    Seynaeve, Caroline
    Kriege, Mieke
    BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1174 - 1178
  • [45] Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers
    Milne, Roger L.
    Antoniou, Antonis C.
    ENDOCRINE-RELATED CANCER, 2016, 23 (10) : T69 - T84
  • [46] No sib pair concordance for breast or ovarian cancer in BRCA1 mutation carriers
    Moller, Pal
    Maehle, Lovise
    Clark, Neal
    Apold, Jaran
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2007, 5 (02) : 67 - 71
  • [47] No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers
    Pål Møller
    Lovise Mæhle
    Neal Clark
    Jaran Apold
    Hereditary Cancer in Clinical Practice, 5
  • [48] Risk of primary and contralateral breast cancer in BRCA1/2 mutation carriers previously affected with ovarian cancer
    Heemskerk-Gerritsen, B. A. M.
    Hooning, M. J.
    van Doorn, H. C.
    Collee, M.
    Koppert, L. B.
    Jager, A.
    van den Ouweland, A. M. W.
    Seynaeve, C.
    Kriege, M.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 528 - 528
  • [49] Risk of primary and contralateral breast cancer in BRCA1/2 mutation carriers previously affected with ovarian cancer
    Heemskerk-Gerritsen, B. A. M.
    Hooning, M. J.
    van Doorn, H. C.
    Collee, M. J.
    Koppert, L. B.
    Jager, A.
    van den Ouweland, A. M. W.
    Netherlands, H.
    Seynaeve, C.
    Kriege, M.
    CANCER RESEARCH, 2017, 77
  • [50] Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers
    Eisen, Andrea
    Lubinski, Jan
    Gronwald, Jacek
    Moller, Pal
    Lynch, Henry T.
    Klijn, Jan
    Kim-Sing, Charmaine
    Neuhausen, Susan L.
    Gilbert, Lucy
    Ghadirian, Parviz
    Manoukian, Siranoush
    Rennert, Gad
    Friedman, Eitan
    Isaacs, Claudine
    Rosen, Eliot
    Rosen, Barry
    Daly, Mary
    Sun, Ping
    Narod, Steven A.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (19) : 1361 - 1367
12345